Vedolizumab may be an effective induction and maintenance treatment for patients who have moderate to severe Crohn's disease, according to a study presented at the American College of Gastroenterology's annual meeting. The drug showed greater efficacy than placebo in maintaining clinical remission, clinical response and corticosteroid-free remission in the study of 1,116 Crohn's disease patients.

Related Summaries